Cresco Labs is trading 5.72% down now at $0.70 after investors continued digesting August 6 earnings report.

  • Q2 revenue and adjusted EBITDA exceeded expectations, but management projected roughly flat sequential Q3 revenue and warned of gross-margin pressure from higher-cost inventory and facility upgrades.
  • Reported CFO departure adds leadership-transition risk; broader cannabis shares remained under pressure, while the overall market was modestly lower.
  • The catalyst appears to be post-earnings caution, not a fresh August 10 announcement.